Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMRXW9P)

Drug Name

GSK-2130579A Drug Info

Synonyms

Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMRXW9P

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Wilms tumor protein (WT1)	TTZ8UT4	WT1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Wilms tumor protein (WT1)	DTT	WT1	3.256	2.655	5.113	2.963

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Acute myeloid leukaemia

ICD Disease Classification

2A60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Wilms tumor protein (WT1)	DTT	WT1	5.12E-79	1.54	7.84

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01051063) Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy. U.S. National Institutes of Health.
2	Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012.